Further assessment of the clinically effective dose range of etoricoxib: a randomized, double-blinded, placebo-controlled trial in rheumatoid arthritis

References

• Pincus T. Long-term outcomes in rheumatoid arthritis. Br J Rheumatol 1995;34(Suppl 2):59-73
   PubMedGoogle Scholar
• Vane JR. The fight against rheumatism: from willow bark to COX-1 sparing drugs. J Physiol Pharmacol 2000;51(4 Pt 1):573-86
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5
   PubMedGoogle Scholar
• Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. Am J Ther 2001;8:123-43
   Google Scholar
• Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 2: the newer drugs and drug strategies. Am J Ther 2001;8:163-79
   PubMedGoogle Scholar
• Blom M, van Riel PL. Management of established rheumatoid arthritis with an emphasis on pharmacotherapy. Best Pract Res Clin Rheumatol 2007;21:43-57
   PubMed Web of Science ®Google Scholar
• Schweinhardt P, Kalk N, Wartolowska K, et al. Investigation into the neural correlates of emotional augmentation of clinical pain. Neuroimage 2008;40:759-66
   PubMed Web of Science ®Google Scholar
• Brater DC. Clinical aspects of renal prostaglandins and NSAID therapy. Semin Arthritis Rheum 1988;17(3 Suppl 2):17-22
   PubMed Web of Science ®Google Scholar
• Murray MD, Brater DC. Effects of NSAIDs on the kidney. Prog Drug Res 1997;49:155-71
   PubMedGoogle Scholar
• Laine L, Goldkind L, Curtis SP, et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol 2009;104:356-62
   PubMed Web of Science ®Google Scholar
• Thiefin G, Schaeverbeke T, Barthelemy P, et al. Upper gastrointestinal symptoms in patients treated with nonsteroidal anti-inflammatory drugs: prevalence and impact – the COMPLAINS study. Eur J Gastroenterol Hepatol 2010;22:81-7
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8
   PubMed Web of Science ®Google Scholar
• Martin-Mola E, Balsa A. Infectious complications of biologic agents. Rheum Dis Clin North Am 2009;35:183-99
   PubMed Web of Science ®Google Scholar
• Sandoval DM, Alarcon GS, Morgan SL. Adverse events in methotrexate-treated rheumatoid arthritis patients. Br J Rheumatol 1995; (34 Suppl 2):49-56
   PubMedGoogle Scholar
• Runge LA. Risk/benefit analysis of hydroxychloroquine sulfate treatment in rheumatoid arthritis. Am J Med 1983;75:52-6
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990;33:1449-61
   PubMed Web of Science ®Google Scholar
• Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am 2004;30:237-55
   PubMed Web of Science ®Google Scholar
• Woodcock J. A difficult balance – pain management, drug safety, and the FDA. N Engl J Med 2009;361:2105-7
   PubMed Web of Science ®Google Scholar
• Sigurdardottir SL, Freysdottir J, Vikingsdottir T, et al. Do non-steroidal anti-inflammatory drugs influence chronic inflammation? The effects of piroxicam on chronic antigen-induced arthritis in rats. Scand J Rheumatol 2008;37:469-76
   PubMed Web of Science ®Google Scholar
• Wolfe F, Boers M, Felson D, et al. Remission in rheumatoid arthritis: physician and patient perspectives. J Rheumatol 2009;36:930-3
   PubMed Web of Science ®Google Scholar
• Lee YC, Cui J, Lu B, et al. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. Arthritis Res Ther 2011;13:R83
   PubMed Web of Science ®Google Scholar
• Wilson AW, Medhurst SJ, Dixon CI, et al. An animal model of chronic inflammatory pain: pharmacological and temporal differentiation from acute pain models. Eur J Pain 2006;10:537-49
   PubMed Web of Science ®Google Scholar
• Matsumoto AK, Melian A, Mandel DR, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002;29:1623-30
   PubMed Web of Science ®Google Scholar
• Collantes E, Curtis SP, Lee KW, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract 2002;3:10
   PubMedGoogle Scholar
• Etoricoxib 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets: summary of product characteristics. Available at: http://www.medicines.org.uk/EMC/medicine/8734/SPC/Arcoxia+30 mg,+60+mg,+90+mg+%26+120+mg+Film-coated+Tablets/ [Last accessed 9 February 2011]
   Google Scholar
• Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35
   PubMed Web of Science ®Google Scholar
• Passik SD, Kirsh KL, Donaghy KB, et al. Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain 2006;22:173-81
   PubMed Web of Science ®Google Scholar
• Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006;15:618-27
   PubMed Web of Science ®Google Scholar
• Kuehn BM. FDA opioid safety plan promotes patient, physician education to prevent abuse. JAMA 2010;304:845
   PubMed Web of Science ®Google Scholar
• Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010;170:1968-76
   PubMed Web of Science ®Google Scholar
• Curtis SP, Ko AT, Bolognese JA, et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective inhibitor etoricoxib. Curr Med Res Opin 2006;22:2365-74
   PubMed Web of Science ®Google Scholar
• Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771-81
   PubMed Web of Science ®Google Scholar
• Krueger K, Lino L, Dore R, et al. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis 2008;67:315-22
   PubMed Web of Science ®Google Scholar
• Combe B, Swergold G, McLay J, et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford) 2009;48:425-32
   PubMed Web of Science ®Google Scholar
• Baraf HS, Fuentealba C, Greenwald M, et al. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J Rheumatol 2007;34:408-20
   PubMed Web of Science ®Google Scholar
• Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007;369:465-73
   PubMed Web of Science ®Google Scholar
• Ramey DR, Watson DJ, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005;21:715-22
   PubMed Web of Science ®Google Scholar
• Masso Gonzalez EL, Patrignani P, Tacconelli S, et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010;62:1592-601
   PubMed Web of Science ®Google Scholar
• Solomon DH. Strategies for making analgesia safer: the role of comparative effectiveness research. Arthritis Rheum 2010;62:1568-70
   PubMed Web of Science ®Google Scholar